Eutherapeutic Pharmaceutical Ibandronate Sodium CAS 138844-81-2 for Osteoporosis CAS NO.138844-81-2

1. Hubei Jusheng Technology Co., Ltd.,  is a global chemical industry manufacturers and suppliers of pharmaceuticals and intermediates in China.

2. The yearly production capacity is 50000MT, 80% for export.We have a professinal export team. Both by Air and by Sea,we ensure that we meet the customer expectations with promptness.
3. Our company facing global High-tech pharmaceutical raw materials, high complex new type intermediates, fine chemicals custom synthesis, scale-up production and Rare chemicals trade. Corey have well-equipped machine, strong technical force and considerate marketing team service.
4. We also have rich experience advantage in basic research, small scale process development, scale-up, industrial technology development & production and cost control.  

1. Quick Detail:

Ibandronate sodium
Synonym: Sodium [1-hydroxy-1-(hydroxy-oxido-phosphoryl)-3-(methyl-pentyl-amino) propyl]phosphonic acid; (1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonic acid monosodium salt; Ibandronate Sodium Anhydrous; Bondronat, (1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonic acid sodium; Ibandronate sodium; Bondronat; Ibandronate sodiuM Bondronat
InChI: InChI=1/C9H23NO7P2. Na/c1-3-4-5-7-10(2)8-6-9(11, 18(12, 13)14)19(15, 16)17; /h11H, 3-8H2, 1-2H3, (H2, 12, 13, 14)(H2, 15, 16, 17); /q; +1/p-1
Purity: 99%
CAS No.: 138844-81-2
MF: C9H22NNaO7P2
MW: 341.21
Boiling Point: 587.8 ° C at 760 mmHg
Vapour: 2.88E-16mmHg at 25° C
Flash Point: 309.3 ° C
Storage temp: 2-8° C
Appearance: White crystalline powder
Grade: Pharmaceutical Grade
Place of Origin: Wuhan, China
 

Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. In May 2003, the U. S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug.
Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers.